tiprankstipranks
Akari Therapeutics (AKTX)
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price & Analysis

272 Followers

AKTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.08 - $5.50
Previous Close$2.52
Volume30.21K
Average Volume (3M)22.40K
Market Cap
$18.27M
Enterprise Value$16.33M
Total Cash (Recent Filing)$3.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)
Beta1.09
Sep 26, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,923,696
10 Day Avg. Volume34,042
30 Day Avg. Volume22,401
Standard Deviation0.18
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)11.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

AKTX FAQ

What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $1.08 and its highest was $5.50 in the past 12 months.
    What is Akari Therapeutics’s market cap?
    Currently, no data Available
    When is Akari Therapeutics’s upcoming earnings report date?
    Akari Therapeutics’s upcoming earnings report date is Sep 26, 2024 which is in 106 days.
      How were Akari Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Akari Therapeutics overvalued?
      According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Akari Therapeutics pay dividends?
        Akari Therapeutics does not currently pay dividends.
        What is Akari Therapeutics’s EPS estimate?
        Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Akari Therapeutics have?
        Akari Therapeutics has 7,923,696 shares outstanding.
          What happened to Akari Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Akari Therapeutics?
          Currently, no hedge funds are holding shares in AKTX
          ---

          Akari Therapeutics Stock Smart Score

          Company Description

          Akari Therapeutics

          Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Adverum Biotechnologies
          Anika Therapeutics
          Oncolytics Biotech
          Protagonist Therapeutics
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis